Home » Lilly, Daiichi’s Prasugrel Wins Advisory Committee Recommendation
Lilly, Daiichi’s Prasugrel Wins Advisory Committee Recommendation
An FDA advisory committee voted unanimously to recommend approval of Eli Lilly and Daiichi Sankyo’s anti-clotting drug prasugrel to treat acute coronary syndrome despite a risk of bleeding. The Cardiovascular and Renal Drugs Advisory Committee agreed that prasugrel, like Plavix (clopidogrel bisulfate), is superior to placebo and probably is superior to Plavix in terms of effectiveness.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May